137 related articles for article (PubMed ID: 27906635)
1. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.
Giovannetti E; Leon LG; Gómez VE; Zucali PA; Minutolo F; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):643-651. PubMed ID: 27906635
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.
Maftouh M; Avan A; Sciarrillo R; Granchi C; Leon LG; Rani R; Funel N; Smid K; Honeywell R; Boggi U; Minutolo F; Peters GJ; Giovannetti E
Br J Cancer; 2014 Jan; 110(1):172-82. PubMed ID: 24178759
[TBL] [Abstract][Full Text] [Related]
3. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
Li Petri G; El Hassouni B; Sciarrillo R; Funel N; Mantini G; Zeeuw van der Laan EA; Cascioferro S; Avan A; Zucali PA; Zaffaroni N; Lagerweij T; Parrino B; Smid K; Deraco M; Granchi C; Braczko A; Smolenski RT; Matherly LH; Jansen G; Assaraf YG; Diana P; Cloos J; Peters GJ; Minutolo F; Giovannetti E
Br J Cancer; 2020 Aug; 123(4):644-656. PubMed ID: 32493992
[TBL] [Abstract][Full Text] [Related]
4. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Wang H; Word BR; Lyn-Cook BD
Anticancer Res; 2011 Oct; 31(10):3171-80. PubMed ID: 21965724
[TBL] [Abstract][Full Text] [Related]
6. GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
Tang Y; Cong X; Wang S; Fang S; Dong X; Yuan Y; Fan J
Biochem Biophys Res Commun; 2018 Sep; 503(4):3142-3148. PubMed ID: 30143259
[TBL] [Abstract][Full Text] [Related]
7. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
8. New Imidazo[2,1-
Li Petri G; Pecoraro C; Randazzo O; Zoppi S; Cascioferro SM; Parrino B; Carbone D; El Hassouni B; Cavazzoni A; Zaffaroni N; Cirrincione G; Diana P; Peters GJ; Giovannetti E
Anticancer Res; 2020 Sep; 40(9):4913-4919. PubMed ID: 32878779
[TBL] [Abstract][Full Text] [Related]
9. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
[TBL] [Abstract][Full Text] [Related]
11. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
Oguri T; Achiwa H; Muramatsu H; Ozasa H; Sato S; Shimizu S; Yamazaki H; Eimoto T; Ueda R
Cancer Lett; 2007 Oct; 256(1):112-9. PubMed ID: 17658213
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
Zanellato I; Boidi CD; Lingua G; Betta PG; Orecchia S; Monti E; Osella D
Cancer Chemother Pharmacol; 2011 Feb; 67(2):265-73. PubMed ID: 20369238
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
14. Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1).
Zafar M; Naydenova Z; Coe IR
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):631-642. PubMed ID: 27906634
[TBL] [Abstract][Full Text] [Related]
15. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Damaraju VL; Scriver T; Mowles D; Kuzma M; Ryan AJ; Cass CE; Sawyer MB
Clin Cancer Res; 2014 Jan; 20(1):176-86. PubMed ID: 24170548
[TBL] [Abstract][Full Text] [Related]
19. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
Xi Y; Yuan P; Li T; Zhang M; Liu MF; Li B
Cancer Lett; 2020 Jun; 479():112-122. PubMed ID: 32200037
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]